Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Familial Cancer Année : 2018

Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries

Anne Brédart
  • Fonction : Auteur
  • PersonId : 923332
Antonis C. Antoniou
  • Fonction : Auteur
Antoine de Pauw
  • Fonction : Auteur
  • PersonId : 905907
Marc Tischkowitz
  • Fonction : Auteur
Hans Ehrencrona
  • Fonction : Auteur
  • PersonId : 909911
Sylvie Dolbeault
  • Fonction : Auteur
  • PersonId : 864692
Léonore Robieux
Kerstin Rhiem
  • Fonction : Auteur
  • PersonId : 920635
Douglas· F. Easton
  • Fonction : Auteur
Peter Devilee
  • Fonction : Auteur
  • PersonId : 910049
Dominique Stoppa-Lyonnet
Rita Schmutlzer
  • Fonction : Auteur

Résumé

The ‘BOADICEA’ Web Application (BWA) used to assess breast cancer risk, is currently being further developed, to integrate additional genetic and non-genetic factors. We surveyed clinicians’ perceived acceptability of the existing BWA v3. An online survey was conducted through the BOADICEA website, and the British, Dutch, French and Swedish genetics societies. Cross-sectional data from 443 participants who provided at least 50% responses were analysed. Respondents varied in age and, clinical seniority, but mainly comprised women (77%) and genetics professionals (82%). Some expressed negative opinions about the scientific validity of BOADICEA (9%) and BWA v3 risk presentations (7–9%). Data entry time (62%), clinical utility (22%) and ease of communicating BWA v3 risks (13–17%) received additional negative appraisals. In multivariate analyses, controlling for gender and country, data entry time was perceived as longer by genetic counsellors than clinical geneticists (p < 0.05). Respondents who (1) considered hormonal BC risk factors as more important (p < 0.01), and (2) communicated numerical risk estimates more frequently (p < 0.001), judged BWA v3 of lower clinical utility. Respondents who carried out less frequent clinical activity (p < 0.01) and respondents with ‘11 to 15 years’ seniority (p < 0.01) had less favourable opinions of BWA v3 risk presentations. Seniority of ‘6 to 10 years’ (p < 0.05) and more frequent numerical risk communication (p < 0.05) were associated with higher fear of communicating the BWA v3 risks to patients. The level of genetics training did not affect opinions. Further development of BWA should consider technological, genetics service delivery and training initiatives.

Domaines

Psychologie Cancer
Fichier principal
Vignette du fichier
Brédart2018_Article_UseOfTheBOADICEAWebApplication.pdf (732.44 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02275380 , version 1 (02-09-2019)

Identifiants

Citer

Anne Brédart, Jean-Luc Kop, Antonis C. Antoniou, Alex P. Cunningham, Antoine de Pauw, et al.. Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. Familial Cancer, 2018, 17 (1), pp.31-41. ⟨10.1007/s10689-017-0014-x⟩. ⟨hal-02275380⟩
85 Consultations
104 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More